Thank you very much Trojan. There haven't been many studies of both MANF and CDNF and I was curious to read their approach that lead to the combination of the two and the effectiveness.
Also helps to understand why in August Amarantus's IP license with Bascom covers the use of Both MANF and CDNF for retinal diseases.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links